The invention discloses a mucosa M-
cell targeted
viral myocarditis gene vaccine. The vaccine is prepared by compounding a mucosa
delivery system capable of targeting mucosa M-cells and B3-type coxsackie
virus antigen encoding plasmids through cross-linking copolymerization. The invention further discloses a preparation method of the
gene vaccine. The invention further discloses a preparation method of the mucosa
delivery system capable of targeting the mucosa M-cells, and the mucosa
delivery system is acquired after stable
amide-ester bonds are formed by carboxyl groups and amino groups in deacetylated
chitosan, wherein the carboxyl groups in
peptide fragment CPE30 are targeted by M-cells which are activated by using EDC (
Dichloroethane) and NHS (N-Hydroxysuccinimide). By nasally dropping the
gene vaccine onto immunized mice, the gene vaccine is proved to be capable of effectively inducing the response between specific
antigen serum and mucoantibody, obviously enhancing the local specific T-
cell killing ability of the
whole body and
gastrointestinal mucosa and significantly improving the ability of mice for resisting B3-type coxsackie
virus, thereby being an excellent prophylactic vaccine for
viral myocarditis.